文献速递放疗物理与技术乳腺癌放疗

用于癌症治疗的俄歇电子和β粒子发射放射性核素与外部束辐射的体外和临床前系统剂量效应研究

In Vitro and Preclinical Systematic Dose-Effect Studies of Auger Electron- and β Particle-Emitting Radionuclides and External Beam Radiation for Cancer Treatment.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-05-24

本研究在表达人钠碘同向转运体(hNIS)和绿色荧光蛋白的三阴性乳腺癌MDA-MB-231细胞及荷瘤小鼠中,比较了[99mTc]TcO4-、[123I]I-和[188Re]ReO4-的体外克隆形成存活与体内生存,并用MIRD形式计算核吸收剂量、OLINDA/EXM外推人体剂量。结果显示[123I]I-达到37%存活所需衰变数最低,体外杀伤优于X线;体内X线中位生存54天优于[188Re]ReO4-的45天和[123I]I-的43天,放射性核素组未见转移。

要点

  • [123I]I-达到37%存活所需衰变数分别比[99mTc]TcO4-和[188Re]ReO4-低2.4倍和1.5倍(孵育72小时)。
  • 体外[99mTc]TcO4-、[123I]I-和[188Re]ReO4-的细胞杀伤效果优于X线。
  • 体内X线中位生存54天,优于[188Re]ReO4-的45天和[123I]I-的43天;放射性核素组未见转移。

核心结论

  • 首次报告[99mTc]TcO4-、[123I]I-和[188Re]ReO4-在细胞和肿瘤模型中的参考剂量效应数据。
  • 进一步证明[123I]I-和[188Re]ReO4-相比外部束放疗具有肿瘤控制效应。

研究设计与样本

  • 体外使用表达hNIS和GFP的三阴性MDA-MB-231乳腺癌细胞(MDA-MB-231.hNIS-GFP),通过克隆形成实验测定放射性毒性。
  • 体内使用荷原位MDA-MB-231.hNIS-GFP肿瘤的雌性NSG小鼠,与X线处理(12.6-15 Gy)组及未处理组比较。
  • 利用MIRD形式计算核吸收剂量,并用OLINDA/EXM将肿瘤和表达钠碘同向转运体器官的单位活度吸收剂量外推至参考成人模型。

主要发现

  • [99mTc]TcO4-和[123I]I-仅降低表达hNIS细胞的存活分数,而[188Re]ReO4-降低表达hNIS细胞和亲本细胞的存活分数。
  • 孵育72小时后,[123I]I-达到37%存活所需衰变数分别比[99mTc]TcO4-和[188Re]ReO4-低2.4倍和1.5倍。
  • 体外[99mTc]TcO4-、[123I]I-和[188Re]ReO4-的细胞杀伤效果优于X线。
  • 体内X线组中位生存54天,分别长于[188Re]ReO4-组的45天和[123I]I-组的43天。
  • 与X线组不同,放射性核素处理组未观察到转移;[188Re]ReO4-对1 g肿瘤的外推人体吸收剂量在女性和男性模型中分别比[123I]I-高13.8倍和11.2倍。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Despite a rise in clinical use of radiopharmaceutical therapies, the biological effects of radionuclides and their relationship with absorbed radiation dose are poorly understood. Here, we set out to define this relationship for Auger electron emitters [99mTc]TcO4- and [123I]I- and β--particle emitter [188Re]ReO4-. Studies were carried out using genetically modified cells that permitted direct radionuclide comparisons. METHODS AND MATERIALS: Triple-negative MDA-MB-231 breast cancer cells expressing the human sodium iodide symporter (hNIS) and green fluorescent protein (GFP; MDA-MB-231.hNIS-GFP) were used. In vitro radiotoxicity of [99mTc]TcO4-, [123I]I-, and [188Re]ReO4- was determined using clonogenic assays. Radionuclide uptake, efflux, and subcellular location were used to calculate nuclear absorbed doses using the Medical Internal Radiation Dose (MIRD) formalism. In vivo studies were performed using female NSG mice bearing orthotopic MDA-MB-231.hNIS-GFP tumors and compared with X-ray-treated (12.6-15 Gy) and untreated cohorts. Absorbed dose per unit activity in tumors and sodium iodide symporter-expressing organs was extrapolated to reference human adult models using OLINDA/EXM. RESULTS: [99mTc]TcO4- and [123I]I- reduced the survival fraction only in hNIS-expressing cells, whereas [188Re]ReO4- reduced survival fraction in hNIS-expressing and parental cells. [123I]I- required 2.4- and 1.5-fold lower decays/cell to achieve 37% survival compared with [99mTc]TcO4- and [188Re]ReO4-, respectively, after 72 hours of incubation. Additionally, [99mTc]TcO4-, [123I]I-, and [188Re]ReO4- had superior cell killing effectiveness in vitro compared with X-rays. In vivo, X-ray led to a greater median survival compared with [188Re]ReO4- and [123I]I- (54 days vs 45 and 43 days, respectively). Unlike the X-ray cohort, no metastases were visualized in the radionuclide-treated cohorts. Extrapolated human absorbed doses of [188Re]ReO4- to a 1 g tumor were 13.8- and 11.2-fold greater than for [123I]I- in female and male models, respectively. CONCLUSIONS: This work reports reference dose-effect data using cell and tumor models for [99mTc]TcO4-, [123I]I-, and [188Re]ReO4- for the first time. We further demonstrate the tumor-controlling effects of [123I]I- and [188Re]ReO4- in comparison with external beam radiation therapy.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Costa IM, Firth G, Kim J, et al. In Vitro and Preclinical Systematic Dose-Effect Studies of Auger Electron- and β Particle-Emitting Radionuclides and External Beam Radiation for Cancer Treatment. Int J Radiat Oncol Biol Phys. 2024. PMID: 38797497. doi:10.1016/j.ijrobp.2024.05.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。